ClinicalTrials.gg
WithdrawnNCT04355676Updated Jan 20, 2023

Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19

A Phase 2 interventional study of Selinexor in Coronavirus Infection, sponsored by Karyopharm Therapeutics Inc. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-20.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment

Why this study was withdrawn
No participants enrolled

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main purpose of this study is to evaluate the activity, safety and reduction in mortality of two regimens of low dose selinexor (KPT-330) in patients with moderate or severe COVID-19.

02

Conditions studied

  • Coronavirus Infection

Browse trials for

Keywords

  • COVID-19
  • SARS-CoV-2
03

In context

COVID-19 Reclassified

7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.

Browse COVID-19 studies →

Lead sponsor

Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed laboratory diagnosis of SARS-CoV2 by standard approved reverse transcription polymerase chain reaction (RT-PCR) assay or equivalent approved testing (by local labs).
  • Currently hospitalized and consented within the first 48 hours of hospitalization.
  • provided as above (patients must be dosed with study drug within 12 hours of consent).
  • Has symptoms of moderate or severe COVID-19 as demonstrated by:

Moderate COVID-19:

  1. Currently hospitalized and requiring medical care for COVID-19, and
  2. Peripheral capillary oxygen saturation (SpO2, pulse oximetry) > 94% on room air at screening, and
  3. Radiographic evidence of pulmonary infiltrates

Severe COVID-19:

  1. At least one of the following: fever, cough, sore throat, malaise, headache, muscle pain, shortness of breath at rest or with exertion, confusion, or symptoms of severe lower respiratory symptoms including dyspnea at rest or respiratory distress AND
  2. Clinical signs indicative of lower respiratory infection with COVID-19, with at least one of the following: respiratory rate ≥ 30 breaths/minute (min), heart rate ≥ 125/min, Oxygen saturation (SpO2) \<93% on room air or requires > 2L/minute oxygen by NC in order to maintain SaO2 ≥93%, PaO2/FiO2 \<300 millimeter per mercury (mm/hg)

    • Female patients of must have a negative serum pregnancy test at Screening and must use highly effective methods of throughout the study and for 3 months following the last dose of study treatment.
    • Males who are sexually active must commit to use a highly effective method of contraception while receiving selinexor and for 3 months after the last selinexor dose, or consent to total sexual abstinence (abstinence must occur from enrollment and continue for 3 months after the last selinexor dose).

Exclusion criteria

Exclusion Criteria:

  • Evidence of critical COVID-19 based on:

    1. Respiratory failure (defined by endotracheal intubation and mechanical ventilation, oxygen delivered by high-flow nasal cannula, noninvasive positive pressure ventilation, or clinical diagnosis of respiratory failure in setting of resource limitations)
    2. Septic shock (defined by SBP \< 90 mm Hg, or Diastolic BP \< 60 mm Hg)
    3. Multiple organ dysfunction/failure
  • In the opinion of the investigator, unlikely to survive for at least 48 hours from screening or anticipate mechanical ventilation within 48 hours
  • Concurrent anti-viral and/or anti-inflammatory agents (e.g., biologics, hydroxychloroquine) are not permitted.
  • Inadequate hematologic parameters as indicated by the following labs:

    1. Patients with severe neutropenia (ANC \<1,000 x 10\^9/liter [L]) or
    2. Thrombocytopenia (e.g., \<100,000 per microliter of blood)
  • Inadequate renal function as indicated by (CrCl) \<20 milliliter per minute (mL/min) using the formula of Cockcroft and Gault.
  • Inadequate hepatic function defined as or ALT > 5x the OR serum direct > 2.5x the upper limit of normal.
  • Hyponatremia defined as sodium \< 135 milliequivalents per liter (mEq/L).
  • In the opinion of the Investigator, patients who are below their ideal body weight and would be unduly impacted by changes in their weight.
  • Unable to take oral medication when is obtained.
  • Patients with a legal guardian or who are incarcerated.
  • Pregnant and breastfeeding women.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Selinexor 40mg

    Participants will receive 40 milligram (mg) of selinexor as oral tablets on Days 1 and 3 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).

    Drug: Selinexor

  • Experimental
    Selinexor 20mg

    Participants will receive 20 milligram (mg) of selinexor oral tablet on Days 1, 3 and 5 of each week for up to 2 weeks (14 days). If the participant is tolerating therapy and clinically benefitting, dosing can continue for an additional 2 weeks (28 days).

    Drug: Selinexor

Interventions

  • 20 mg selinexor oral tablet.

    Also known as: KPT-330, XPOVIO

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale

    Time frame: Baseline to Day 14

Secondary outcomes

  1. Time to Clinical Improvement (TTCI)

    Time frame: Up to Day 28

  2. Overall Death Rate

    Time frame: Day 14, Day 28

  3. Rate of Mechanical Ventilation

    Time frame: Up to Day 28

  4. Time to Mechanical Ventilation

    Time frame: Up to Day 28

  5. Overall Survival

    Time frame: Up to Day 28

  6. Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale

    Time frame: Up to Day 28

  7. Time to Intensive Care Unit (ICU) Admission

    Time frame: Up to Day 28

  8. Rate of Intensive Care Unit (ICU) Admission

    Time frame: Up to Day 28

  9. Length of Stay in Hospital

    Time frame: Up to Day 28

  10. Percentage of Participants Discharged From Hospital

    Time frame: Up to Day 28

  11. Length of Stay in Intensive Care Unit (ICU)

    Time frame: Up to Day 28

  12. Duration of Oxygen Supplementation

    Time frame: Up to Day 28

  13. Duration of Mechanical Ventilation

    Time frame: Up to Day 28

  14. Time to Clinical Improvement in Participants ≤ 70 Years Old

    Time frame: Up to Day 28

  15. Time to Clinical Improvement in Participants > 70 Years Old

    Time frame: Up to Day 28

  16. Time to Clinical Improvement in Participants with Pre-existing Diseases

    Time frame: Up to Day 28

  17. Change in Oxygenation Index

    Time frame: Up to Day 28

  18. Time to Improvement of One Point Using WHO Ordinal Scale Improvement

    Time frame: Up to Day 28

  19. Percentage of Participants Experiencing WHO Ordinal Scale Improvement of >1 point

    Time frame: Up to Day 28

  20. Change from Baseline in C-reactive protein (CRP) Levels

    Time frame: Up to Day 28

  21. Change from Baseline in Ferritin Levels

    Time frame: Up to Day 28

  22. Change from Baseline in Lactate Dehydrogenase (LDH) Levels

    Time frame: Up to Day 28

  23. Number of Participants with Adverse Events (AE)

    Time frame: From start of study drug administration up to follow-up (Day 30)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2020 to primary completion in Aug 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2020
First posted
Apr 21, 2020
StartActual
Apr 30, 2020
Primary completionActual
Aug 30, 2020
CompletionActual
Aug 30, 2020
Last update
Jan 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04355676
Responsible party
Sponsor
First posted
Apr 21, 2020
Start date
Apr 30, 2020
Primary completion
Aug 30, 2020
Completion
Aug 30, 2020
Last update
Jan 20, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion